FI972775A7 - Uudet kvinuklidiinijohdokset ja näiden lääkinnälliset seokset - Google Patents

Uudet kvinuklidiinijohdokset ja näiden lääkinnälliset seokset

Info

Publication number
FI972775A7
FI972775A7 FI972775A FI972775A FI972775A7 FI 972775 A7 FI972775 A7 FI 972775A7 FI 972775 A FI972775 A FI 972775A FI 972775 A FI972775 A FI 972775A FI 972775 A7 FI972775 A7 FI 972775A7
Authority
FI
Finland
Prior art keywords
quinuclidine derivatives
medicinal mixtures
new quinuclidine
new
medicinal
Prior art date
Application number
FI972775A
Other languages
English (en)
Swedish (sv)
Other versions
FI115631B (fi
FI972775A0 (fi
Inventor
Makoto Takeuchi
Ryo Naito
Masahiko Hayakawa
Yoshinori Okamoto
Yasuhiro Yonetoku
Ken Ikeda
Yasuo Isomura
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI972775(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of FI972775A0 publication Critical patent/FI972775A0/fi
Publication of FI972775A7 publication Critical patent/FI972775A7/fi
Application granted granted Critical
Publication of FI115631B publication Critical patent/FI115631B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
  • Tea And Coffee (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI972775A 1994-12-28 1997-06-27 Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus FI115631B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (en) 1994-12-28 1995-12-27 Novel quinuclidine derivatives and medicinal composition thereof
JP9502713 1995-12-27

Publications (3)

Publication Number Publication Date
FI972775A0 FI972775A0 (fi) 1997-06-27
FI972775A7 true FI972775A7 (fi) 1997-08-22
FI115631B FI115631B (fi) 2005-06-15

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972775A FI115631B (fi) 1994-12-28 1997-06-27 Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus

Country Status (24)

Country Link
US (2) US6017927A (fi)
EP (1) EP0801067B1 (fi)
JP (1) JP3014457B2 (fi)
KR (1) KR100386487B1 (fi)
CN (1) CN1045601C (fi)
AT (1) ATE233761T1 (fi)
AU (1) AU695616B2 (fi)
CA (1) CA2208839C (fi)
DE (2) DE69529844T2 (fi)
DK (1) DK0801067T3 (fi)
ES (1) ES2193208T3 (fi)
FI (1) FI115631B (fi)
FR (1) FR04C0032I2 (fi)
HU (1) HU223778B1 (fi)
LU (1) LU91133I9 (fi)
MX (1) MX9704880A (fi)
NL (1) NL300141I2 (fi)
NO (4) NO2005012I1 (fi)
NZ (1) NZ298144A (fi)
PL (1) PL182344B1 (fi)
PT (1) PT801067E (fi)
RU (1) RU2143432C1 (fi)
TW (1) TW305842B (fi)
WO (1) WO1996020194A1 (fi)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
AU2001266100B9 (en) * 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
WO2002053564A2 (en) 2000-12-28 2002-07-11 Almirall Prodesfarma Ag Quinuclidine derivatives and their use as m3 antagonists
PL208138B1 (pl) * 2001-07-10 2011-03-31 Astellas Pharma Inc Zastosowanie kompozycji farmaceutycznej
RS52522B (sr) * 2001-12-20 2013-04-30 Chiesi Farmaceutici S.P.A. Derivati 1-alkil-1-azoniabiciklo/2.2.2./oktan karbamata i njihova upotreba kao antagonista muskarinskih receptora
KR20050008795A (ko) * 2002-06-07 2005-01-21 야마노우치세이야쿠 가부시키가이샤 과활동 방광 치료제
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
DE60226906D1 (de) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
AU2002321711A1 (en) 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
WO2004018422A1 (en) 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
AU2003269380A1 (en) * 2002-10-29 2004-05-25 Pharmacia & Upjohn Company Llc Quinuclidinium derivatives as antimuscarinic agents
DE60227576D1 (de) 2002-12-10 2008-08-21 Ranbaxy Lab Ltd 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP2006514978A (ja) 2003-04-10 2006-05-18 ランバクシー ラボラトリーズ リミテッド ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
US7560479B2 (en) 2003-04-10 2009-07-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2522071A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
EP1714965A4 (en) * 2004-02-09 2007-12-19 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACINE SUCCINATE
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
CA2560080A1 (en) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Solifenacin-containing composition
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
JP5168711B2 (ja) * 2004-03-25 2013-03-27 アステラス製薬株式会社 ソリフェナシンまたはその塩の固形製剤用組成物
CN1934109B (zh) * 2004-03-25 2010-06-23 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
AU2005319248A1 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
SK6196Y1 (sk) * 2004-12-27 2012-08-06 Astellas Pharma Inc Stable particulate pharmaceutical composition of solifenacin or its salt, mixture for its preparation and tablet comprising same
WO2006070735A1 (ja) * 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US20080255188A1 (en) * 2005-07-11 2008-10-16 Naresh Kumar Muscarinic Receptor Antagonists
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
JP2008535931A (ja) * 2005-12-21 2008-09-04 テバ ファーマシューティカル インダストリーズ リミティド ソリフェナシンの調製方法
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
US20090326230A1 (en) * 2006-07-19 2009-12-31 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US20080114028A1 (en) * 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
US20080091023A1 (en) * 2006-08-03 2008-04-17 Nurit Perlman Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
US20100029944A1 (en) * 2006-11-22 2010-02-04 Corporacion Medichem, S.L. Process for the Synthesis of Solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
KR20100016116A (ko) * 2007-03-30 2010-02-12 메디쳄 쎄.아. 개선된 솔리페나신의 합성공정
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
US20090099365A1 (en) * 2007-07-13 2009-04-16 Nurit Perlman Processes for solifenacin preparation
CN101754760A (zh) * 2007-07-20 2010-06-23 安斯泰来制药株式会社 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
ES2393525T3 (es) 2007-11-02 2012-12-26 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de la vejiga hiperactiva
WO2009087664A1 (en) * 2007-12-04 2009-07-16 Cadila Healthcare Limited Process for preparing chemically and chirally pure solifenacin base and its salts
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
DK2271218T3 (en) 2008-03-27 2017-09-11 Chase Pharmaceuticals Corp USE AND COMPOSITION TO TREAT DEMENS
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PL3067353T3 (pl) * 2008-07-29 2018-04-30 Krka, D.D., Novo Mesto Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
HUE029638T2 (en) * 2009-02-04 2017-03-28 Astellas Pharma Inc Pharmaceutical preparation for oral administration
WO2010103529A1 (en) 2009-03-09 2010-09-16 Megafine Pharma(P) Ltd. A new method for the preparation of solifenacin and new intermediate thereof
EP2415472A4 (en) * 2009-03-30 2013-02-20 Astellas Pharma Inc SOLID PHARMACEUTICAL COMPOSITION WITH SOLUBENACIN AMORPHIC BODY
WO2011048607A1 (en) 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
EP2572717B1 (en) 2010-05-19 2016-06-15 Astellas Pharma Inc. Pharmaceutical composition containing solifenacin
WO2012001481A1 (en) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Novel process for the preparation of solifenacin succinate
WO2012004264A1 (en) 2010-07-05 2012-01-12 Ragactives, S.L.U. Solifenacin salts
WO2012062916A1 (de) 2010-11-11 2012-05-18 Hexal Ag Kristallines solifenacin-succinat
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112013028755A2 (pt) 2011-05-10 2017-01-31 Theravida Inc combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa
EP2723734A1 (en) 2011-06-22 2014-04-30 Isochem Process for the preparation of solifenacin and salts thereof
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
EP2867210A1 (en) * 2012-07-02 2015-05-06 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
HK1208801A1 (en) 2012-08-31 2016-03-18 安斯泰来制药株式会社 Orally administered medical composition
EP2892514A4 (en) 2012-09-05 2016-04-13 Chase Pharmaceuticals Corp Neurotropic Anticholinergic Composition and Method
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
AR093832A1 (es) * 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
KR101823451B1 (ko) * 2013-07-13 2018-01-30 베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
CA2944714C (en) 2014-05-06 2023-05-16 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
EP3724188B1 (en) 2017-12-12 2023-06-07 Arkuda Therapeutics Progranulin modulators and methods of using the same
PL3792260T3 (pl) 2018-05-08 2024-12-02 Nippon Shinyaku Co., Ltd. Związki azabenzimidazolowe i środki farmaceutyczne
KR20220021472A (ko) * 2019-06-12 2022-02-22 아르쿠다 테라퓨틱스 프로그래눌린 조절제 및 이의 사용 방법
WO2021095801A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 アザベンゾイミダゾール化合物及び医薬
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247266B1 (en) * 1986-01-07 1993-03-10 Beecham Group Plc Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP1424021B1 (en) * 2002-11-27 2006-09-13 Selmac S.r.l. Device for positioning and clamping shaped elements and machine equipped with this device

Also Published As

Publication number Publication date
WO1996020194A1 (en) 1996-07-04
DK0801067T3 (da) 2003-06-30
CN1171109A (zh) 1998-01-21
PL182344B1 (pl) 2001-12-31
FI115631B (fi) 2005-06-15
NO2017055I1 (no) 2017-11-06
PL321019A1 (en) 1997-11-24
NL300141I1 (nl) 2004-04-01
KR987000303A (ko) 1998-03-30
FI972775A0 (fi) 1997-06-27
PT801067E (pt) 2003-07-31
LU91133I9 (en) 2018-08-01
EP0801067A4 (en) 1998-03-11
NO973027L (no) 1997-08-28
RU2143432C1 (ru) 1999-12-27
DE122004000048I1 (de) 2005-04-21
ES2193208T3 (es) 2003-11-01
NZ298144A (en) 1998-04-27
TW305842B (fi) 1997-05-21
DE69529844D1 (de) 2003-04-10
FR04C0032I2 (fr) 2005-10-21
NO2005016I1 (no) 2005-08-29
NO318026B1 (no) 2005-01-24
ATE233761T1 (de) 2003-03-15
EP0801067B1 (en) 2003-03-05
JP3014457B2 (ja) 2000-02-28
US6174896B1 (en) 2001-01-16
JPH09508401A (ja) 1997-08-26
AU4355396A (en) 1996-07-19
US6017927A (en) 2000-01-25
CN1045601C (zh) 1999-10-13
CA2208839C (en) 2006-01-31
CA2208839A1 (en) 1996-07-04
HU223778B1 (hu) 2005-01-28
NO2005016I2 (no) 2008-02-11
NO973027D0 (no) 1997-06-27
DE69529844T2 (de) 2004-03-04
FR04C0032I1 (fi) 2005-02-11
DE122004000048I2 (de) 2006-02-02
MX9704880A (es) 1997-10-31
NO2017055I2 (no) 2017-11-06
LU91133I2 (fr) 2005-03-29
AU695616B2 (en) 1998-08-20
HUT77006A (hu) 1998-03-02
EP0801067A1 (en) 1997-10-15
NL300141I2 (nl) 2004-04-01
NO2005012I1 (no) 2005-06-06
KR100386487B1 (ko) 2003-09-26

Similar Documents

Publication Publication Date Title
FI972775A7 (fi) Uudet kvinuklidiinijohdokset ja näiden lääkinnälliset seokset
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
FI20000516A7 (fi) Bis-indolyylimaleimidijohdannaiset ja niiden valmistus
FI955051A0 (fi) Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
FI941137A7 (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI935074A7 (fi) Uusia tiopyranopyrrolijohdannaisia ja niiden valmistus
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
FI955235L (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
FI961599A7 (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
FI934220A7 (fi) Piperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
FI954204A7 (fi) Ruiskeena annettavat liposomilääkevalmisteet
FI954763A7 (fi) Oksiinijohdannaiset, niiden valmistus ja niiden terapeuttinen käyttö
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
FI914611A7 (fi) 2-aminopyrimidiini-4-karboksamidijohdannaiset, niiden valmistus ja terapeuttinen käyttö
FI971364L (fi) Kolkisiinijohdannaiset ja niiden terapeuttinen käyttö
FI965193A7 (fi) Triterpeenijohdannainen ja lääkeseos
FI964482A7 (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
BR9509688A (pt) Composto e composição farmacêutica
FI964267A7 (fi) Porfosyaniini ja CNC-laajennetut porfyriinit
FI934221A7 (fi) Piperidiinijohdannaiset, niiden valmistus ja terapeuttinen käyttö
FI941958A7 (fi) 2-heterosyklinenetyyliamiinijohdannaiset ja niiden käyttö lääkkeinä
FI981359L (fi) Uudet tiomarinolin johdannaiset ja menetelmät niiden valmistamiseksi
FI944728L (fi) Uudet perhydroisoindolijohdannaiset ja niiden valmistus
FI963130L (fi) Heterosykliset yhdisteet sekä niiden valmistus ja käyttö

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115631

Country of ref document: FI

SPCF Supplementary protection certificate application filed
PC Transfer of assignment of patent

Owner name: ASTELLAS PHARMA INC.

Free format text: ASTELLAS PHARMA INC.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 272

Extension date: 20181216

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20050024

SPCX Supplementary protection certificate: correction

Spc suppl protection certif: 272

Extension date: 20190622